Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Recruiting
Phase 3
Interventional Study
Engraftment Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 110 (estimated)
- Sponsor
- Henry Ford Health System · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* • Patients 18-80 years of age with a diagnosis of a hematological malignancy
* Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies
Exclusion Criteria:
* • Patients enrolled in investigational clinical trials
* Sc…
Contacts